{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:09Z","timestamp":1767665829952,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,12,2]],"date-time":"2004-12-02T00:00:00Z","timestamp":1101945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Pramlintide, a human amylin analogue, is a potential new adjunctive therapy to insulin for patients with type 1 diabetes and insulin\u2010using patients with type 2 diabetes. Early clinical trials have shown a transient increased risk of hypoglycaemia in some patients at the time of initiating pramlintide therapy. This may be the result of combining the postprandial glucose, lowering effect of pramlintide with the existing hypoglycaemic potential of insulin without appropriate adjustment of insulin doses. However, the possibility that pramlintide may exert an independent detrimental effect on the physiological responses to insulin\u2010induced hypoglycaemia needs to be excluded.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    We conducted three separate randomized, placebo\u2010controlled studies in patients with type 1 diabetes treated with adjunctive pramlintide. These studies utilized pramlintide at high doses (either 0.1\u20131\u2003mg pramlintide daily or 0.1\u20130.8\u2003mg pramlintide four times a day for 5 or 6\u2003days) as well as doses closer to those anticipated for therapeutic usage (30, 100 or 300\u2003\u00b5g three times daily for 14\u2003days), and examined the hormonal, metabolic and symptomatic responses to an insulin\u2010infusion hypoglycaemic challenge conducted at baseline and after days of therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results and conclusion:\u2002<\/jats:bold>\n                    Pramlintide had no effect on the counter\u2010regulatory hormonal, metabolic and symptomatic responses to hypoglycaemia. These findings demonstrated that pramlintide, when used as adjunctive therapy to insulin in patients with type 1 diabetes, has no independent effect on the response to hypoglycaemia.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2004.00417.x","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T22:05:23Z","timestamp":1174428323000},"page":"504-516","source":"Crossref","is-referenced-by-count":22,"title":["The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin\u2010induced hypoglycaemia in patients with type 1 diabetes"],"prefix":"10.1111","volume":"7","author":[{"given":"S. A.","family":"Amiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. A.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. J.","family":"Klaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Ruggles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. G.","family":"Kolterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. G.","family":"Maggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,12,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90605-W"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.2.271"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1991.260.5.E705"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.41.3.255"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.3.724"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150252924094"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150260007390"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.20.3.137"},{"issue":"1","key":"e_1_2_6_13_2","first-page":"238A","article-title":"24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls","volume":"44","author":"Koda JE","year":"1995","journal-title":"Diabetes"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90785-2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403957"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-199708000-00006"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2000.278.6.G946"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050949"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.32022"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.46.4.632"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303033080903"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.3.1083"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116302"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.182.4108.171"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.2.134"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197108192850806"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111519"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400639"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-34790"},{"issue":"1","key":"e_1_2_6_32_2","first-page":"A154","article-title":"Amylin inhibition of arginine\u2010induced glucagon secretion: comparison with glucagon\u2010like\u2010peptide\u20101 (7\u201336): \u2010amide (GLP\u20101)","volume":"39","author":"Gedulin B","year":"1996","journal-title":"Diabetologia"},{"issue":"1","key":"e_1_2_6_33_2","first-page":"238A","article-title":"Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats","volume":"40","author":"Gedulin B","year":"1997","journal-title":"Diabetes"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.280.3.E443"},{"journal-title":"Diabetic Med","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long\u2010term glycemic and weight control in type 1 diabetes mellitus: a one year randomized controlled trial","author":"Ratner RE","key":"e_1_2_6_35_2"},{"key":"e_1_2_6_36_2","first-page":"A113","article-title":"Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes","volume":"48","author":"Fineman M","year":"1999","journal-title":"Diabetes"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381302"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.7.1226"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2004.00417.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2004.00417.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:09:36Z","timestamp":1761876576000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2004.00417.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,2]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1463-1326.2004.00417.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2004.00417.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2004,12,2]]}}}